A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

NCT04866485 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: HBM4003 and pembrolizumab

Sponsor

Harbour BioMed (Guangzhou) Co. Ltd.